Joining the Eagle team in May 2021, Ryan serves as Executive Vice President, General Counsel and Chief Compliance Officer. He has over 20 years of experience as a life sciences legal professional and executive, including more than 10 years at Mylan (now Viatris), principally as Vice President and General Counsel, North America.

He has previous experience serving as principal lead for numerous litigations, administrative proceedings, and investigations before federal and state agencies for global pharmaceutical companies, including Sun Pharma and Taro. Ryan earned his J.D. graduating Cum Laude from Duquesne University School of Law and holds a B.S. from University of Michigan.

Dan is our Chief Strategy Officer and Head of Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.

Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.

Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.

John joined Eagle in August of 2020 with a track record of results-driven performance based on a strong strategic decision making and analytical skill set. He brings over 20 years of leadership experience in both commercial and operational functions. Prior to joining Eagle, he held an executive role at Celgene / Bristol Myers Squibb as the Head of Strategic Planning and Decision Analysis.

Between Verizon and Vodafone, John spent 17 years in the telecommunications industry. He held various positions with increasing responsibility in Marketing, Analytics, and Operations.

Valuing education, John holds a Master’s in Business Analytics from NYU’s Stern School of Business, a Global Executive MBA from the Fuqua School of Business at Duke University, and has completed programs at Columbia Business School, and Northwestern University’s Kellogg School of Management.

Debra joined Eagle as part of Eagle’s 2022 acquisition of Acacia Pharma with 25 years of pharmaceutical industry experience. As Chief Commercial Officer for Acacia, Debra had responsibility for BARHEMSYS® and BYFAVO®. Prior to Acacia, Debra spent 22 years at Eli Lilly and Company in positions of increasing responsibility, where she led the U.S. launches of multiple products. Debra has extensive experience in hospital-based sales and marketing across cardiovascular, urology, diabetes, neuroscience, osteoporosis, and critical care/anesthesia specialties.

Debra holds a B.S. from the University of Wisconsin-Milwaukee and a Master’s degree in Audiology from Memphis State University.

Reed joined Eagle with more than 30 years of commercial experience and 25 years of pharmaceutical leadership across multiple commercial functions. His oncology/hematology experience spans 16+ years with Novartis, Celgene, and Bristol-Myers Squibb (BMS). Prior to joining Eagle, Reed led the $12B multiple myeloma franchise at Celgene/BMS. Prior to Celgene, Reed spent 13 years at Novartis in positions of increasing responsibility in both Canada and the U.S.

Reed earned his B.S. in biology from Mount Allison University, NB, Canada.